TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets trimmed its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 17.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 117,985 shares of the biopharmaceutical company's stock after selling 24,661 shares during the quarter. BNP Paribas Financial Markets owned 0.08% of TG Therapeutics worth $2,760,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. NBC Securities Inc. grew its stake in shares of TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 485 shares in the last quarter. Blue Trust Inc. boosted its position in shares of TG Therapeutics by 127.3% during the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 849 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in shares of TG Therapeutics during the 2nd quarter worth about $35,000. ORG Wealth Partners LLC purchased a new stake in TG Therapeutics during the third quarter worth approximately $53,000. Finally, Values First Advisors Inc. acquired a new position in TG Therapeutics in the third quarter valued at approximately $58,000. Hedge funds and other institutional investors own 58.58% of the company's stock.

Analyst Ratings Changes

TGTX has been the subject of several recent analyst reports. JPMorgan Chase & Co. boosted their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research report on Monday, November 25th. HC Wainwright upped their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. TD Cowen began coverage on TG Therapeutics in a report on Tuesday, October 29th. They set a "buy" rating and a $50.00 price objective on the stock. Finally, The Goldman Sachs Group upped their target price on TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $40.67.

TG Therapeutics Stock Performance

Shares of TGTX traded up $0.28 during mid-day trading on Friday, hitting $33.93. 1,317,530 shares of the company's stock were exchanged, compared to its average volume of 3,636,542. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a fifty-two week low of $12.84 and a fifty-two week high of $36.84. The business's 50 day moving average is $27.44 and its two-hundred day moving average is $22.72. The firm has a market capitalization of $5.28 billion, a P/E ratio of -336.47 and a beta of 2.25.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. During the same period in the previous year, the business posted $0.73 earnings per share. The firm's revenue was down 49.4% compared to the same quarter last year. On average, equities analysts expect that TG Therapeutics, Inc. will post 0.17 earnings per share for the current year.

Insiders Place Their Bets

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the transaction, the director now directly owns 100,195 shares of the company's stock, valued at approximately $3,049,935.80. This trade represents a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 10.50% of the company's stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.